Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Robak Tadeusz and Jin Jie and Pylypenko Halyna and Verhoef Gregor and Siritanaratkul Noppadol and Drach Johannes and Raderer Markus and Mayer Jiri and Pereira Juliana and Tumyan Gayane and Okamoto Rumiko and Demeter Judit and Egyed Miklós and Borbényi Zita and et al. (kollab. közrem.): Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
LANCET ONCOLOGY, 19 (11). pp. 1449-1458. ISSN 1470-2045 (2018)

[thumbnail of Robak.pdf]
Preview
Text
Robak.pdf - Published Version

Download (725kB) | Preview
Item Type: Journal Article
Szerzők száma: 127
Journal or Publication Title: LANCET ONCOLOGY
Date: 2018
Volume: 19
Number: 11
Page Range: pp. 1449-1458
ISSN: 1470-2045
Faculty/Unit: Faculty of Medicine
Institution: Szegedi Tudományegyetem
Language: English
MTMT rekordazonosító: 30972282
DOI azonosító: https://doi.org/10.1016/S1470-2045(18)30685-5
Date Deposited: 2022. Dec. 02. 11:36
Last Modified: 2022. Dec. 02. 11:40
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/25682
Web of Science® Times Cited: 77 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year